Mesoblast (MESO) Raw Materials (2025)
Mesoblast's (MESO) quarterly Raw Materials came in at -$4.5 million in Q4 2025, down 525.4% quarter-over-quarter from $1.1 million in Q2 2025.
Mesoblast (MESO) Raw Materials (2025) Analysis & Trends
Mesoblast has disclosed Raw Materials across 1 years of filings, most recently posting -$4.5 million for Q4 2025.
- Raw Materials for Q4 2025 came in at -$4.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.5 million (changed N/A YoY), and the FY2025 annual result was $1.1 million, changed N/A from the prior year.
- Raw Materials came in at -$4.5 million for Q4 2025 at Mesoblast, down from $1.1 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $1.1 million in Q2 2025 to a low of -$4.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.52 Mn |
| Jun 30, 2025 | 1.06 Mn |